FDA grants IND clearance for TG Therapeutics’ trial of multiple sclerosis treatment

Precision Biosciences’ partner TG Therapeutics has obtained clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application to commence Phase I clinical trial of Azercabtagene Zapreleucel (azer-cel) for progressive forms of multiple sclerosis (MS).